

Sabina Chiaretti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1676698/publications.pdf>

Version: 2024-02-01

153
papers

11,044
citations

61984

43
h-index

30922

102
g-index

153
all docs

153
docs citations

153
times ranked

15936
citing authors

#	ARTICLE	IF	CITATIONS
1	Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study. <i>Haematologica</i> , 2022, 107, 996-999.	3.5	15
2	Blast morphology in the diagnostic work-up of Ph-like acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2022, , 1-3.	1.3	0
3	Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease–positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	1
4	COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report. <i>Haematologica</i> , 2022, 107, 1955-1959.	3.5	6
5	Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2022, 386, 2399-2411.	27.0	31
6	Digital Droplet PCR Is a Reliable Tool to Improve Minimal Residual Disease Stratification in Adult Philadelphia-Negative Acute Lymphoblastic Leukemia. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 893-900.	2.8	7
7	Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913. <i>Haematologica</i> , 2021, 106, 1559-1568.	3.5	49
8	Ponatinib for the treatment of Ph-like acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 755-757.	1.3	6
9	Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase <i>II</i> pediatric–like <i>GIMEMA LAL</i> –1308 trial. <i>American Journal of Hematology</i> , 2021, 96, 292-301.	4.1	21
10	A multicenter total therapy strategy for <i>de novo</i> adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol. <i>Haematologica</i> , 2021, 106, 1828-1838.	3.5	33
11	<i>MYB</i> rearrangements and overexpression in <i>cell</i> acute lymphoblastic leukemia. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 482-488.	2.8	12
12	Prognostic impact of <i>KMT2A</i> – <i>AFF1</i> positivity in 926 <i>BCR</i> – <i>ABL1</i> –negative <i>B</i> –lineage acute lymphoblastic leukemia patients treated in <i>GIMEMA</i> clinical trials since 1996. <i>American Journal of Hematology</i> , 2021, 96, E334-E338.	4.1	3
13	Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab. <i>Blood</i> , 2021, 138, 2290-2293.	1.4	15
14	Emerging tyrosine kinase inhibitors for the treatment of adult acute lymphoblastic leukemia. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 281-294.	2.4	3
15	Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia–positive acute lymphoblastic leukaemia. <i>Hematological Oncology</i> , 2021, 39, 680-686.	1.7	12
16	HEMATOLOGY PATIENT PROTECTION DURING THE COVID-19 PANDEMIC IN ITALY: A NATIONWIDE NURSING SURVEY. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2021, 13, e2021011.	1.3	2
17	Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 804714.	2.8	9
18	Efficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with <i>Ebf1-Pdgfrb</i> fusion transcript. <i>Leukemia and Lymphoma</i> , 2020, 61, 469-472.	1.3	12

#	ARTICLE	IF	CITATIONS
19	In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent. <i>Leukemia</i> , 2020, 34, 929-931.	7.2	6
20	National Italian Delphi panel consensus: which measures are indicated to minimize pegylated-asparaginase associated toxicity during treatment of adult acute lymphoblastic leukemia?. <i>BMC Cancer</i> , 2020, 20, 956.	2.6	1
21	Dasatinib+Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. <i>New England Journal of Medicine</i> , 2020, 383, 1613-1623.	27.0	279
22	Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study. <i>American Journal of Hematology</i> , 2020, 95, 1466-1472.	4.1	42
23	Is Less More? Intensive Versus Non-Intensive Approach to Adults with Ph+ ALL. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S54-S55.	0.4	1
24	Philadelphia-positive acute lymphoblastic leukaemia (ALL) in Italy during the COVID-19 pandemic: a Campus ALL study. <i>British Journal of Haematology</i> , 2020, 190, e3-e5.	2.5	27
25	Design of a Comprehensive Fluorescence in Situ Hybridization Assay for Genetic Classification of T-Cell Acute Lymphoblastic Leukemia. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 629-639.	2.8	18
26	Practical guidance for the management of acute lymphoblastic leukemia in the adolescent and young adult population. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072090353.	2.5	23
27	A review of current induction strategies and emerging prognostic factors in the management of children and adolescents with acute lymphoblastic leukemia. <i>Expert Review of Hematology</i> , 2020, 13, 755-769.	2.2	8
28	Autologous stem cell transplant in acute lymphoblastic leukemia: prognostic impact of pre-transplant minimal residual disease. <i>Leukemia and Lymphoma</i> , 2019, 60, 274-276.	1.3	3
29	Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances. <i>Frontiers in Oncology</i> , 2019, 9, 726.	2.8	85
30	Phase II trial with sequential clofarabine and cyclophosphamide for refractory and relapsed philadelphia-negative adult acute lymphoblastic leukemia. Results of the GIMEMA LAL 1610 protocol. <i>Leukemia and Lymphoma</i> , 2019, 60, 3482-3492.	1.3	3
31	Ph+ ALL: How Can We Optimize Treatment for All Patients?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S66-S70.	0.4	0
32	Atypical Chronic Myeloid Leukemia in a Patient with Aplastic Anemia. <i>Acta Haematologica</i> , 2019, 142, 185-186.	1.4	1
33	Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 2838-2840.	1.3	24
34	IL7R overexpression in adult acute lymphoblastic leukemia is associated to JAK/STAT pathway mutations and identifies patients who could benefit from targeted therapies. <i>Leukemia and Lymphoma</i> , 2019, 60, 829-832.	1.3	10
35	Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2019, 104, 312-318.	3.5	54
36	BCR/ABL1-like acute lymphoblastic leukemia: How to diagnose and treat?. <i>Cancer</i> , 2019, 125, 194-204.	4.1	51

#	ARTICLE	IF	CITATIONS
37	Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2019, 54, 788-800.	2.4	106
38	Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph+ ALL Patients. Updated Results of the Gimema LAL2116 D-Alba Trial. <i>Blood</i> , 2019, 134, 740-740.	1.4	30
39	Treatment of Adults with Minimal Residual Disease (MRD) Positive Acute Lymphoblastic Leukemia with Blinatumomab in a Real-World Setting: Results from the Neuf Study. <i>Blood</i> , 2019, 134, 2624-2624.	1.4	1
40	Rapid identification of <i>BCR/ABL</i> like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time polymerase chain reaction: clinical, prognostic and therapeutic implications. <i>British Journal of Haematology</i> , 2018, 181, 642-652.	2.5	46
41	"Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions" Treatment of ALL. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 301-310.	0.4	6
42	High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK/STAT activation or <i>t(6;7)(p21;q34)/TRB@-PIM1</i> rearrangement. <i>Leukemia</i> , 2018, 32, 1807-1810.	7.2	20
43	Genetic landscape of ultra-stable chronic lymphocytic leukemia patients. <i>Annals of Oncology</i> , 2018, 29, 966-972.	1.2	19
44	Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms. <i>Oncotarget</i> , 2018, 7, e1341032.	4.6	11
45	Chemotherapy-free and reduced intensity approaches in elderly patients with B-lineage acute lymphoblastic leukemia. <i>European Journal of Internal Medicine</i> , 2018, 58, 22-27.	2.2	3
46	New Approaches to the Management of Adult Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 3504-3519.	1.6	67
47	Comparative Analysis between RQ-PCR, Digital-Droplet-PCR and Next-Generation-Sequencing (NGS) of Immunoglobulin/T-Cell Receptor Gene Rearrangements to Monitor Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia Patients. <i>Blood</i> , 2018, 132, 2828-2828.	1.4	2
48	Clinical significance of recurrent copy number aberrations in B-lineage acute lymphoblastic leukaemia without recurrent fusion genes across age cohorts. <i>British Journal of Haematology</i> , 2017, 178, 583-587.	2.5	23
49	Advances in the Genetics and Therapy of Acute Lymphoblastic Leukemia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e314-e322.	3.8	28
50	Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes. <i>Oncotarget</i> , 2016, 7, 13886-13901.	1.8	20
51	Comparative analysis between RQ-PCR and digital droplet PCR of immunoglobulin/T cell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2016, 174, 541-549.	2.5	59
52	Inter- and intra-patient clonal and subclonal heterogeneity of chronic lymphocytic leukaemia: evidences from circulating and lymph nodal compartments. <i>British Journal of Haematology</i> , 2016, 172, 371-383.	2.5	20
53	A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study. <i>Haematologica</i> , 2016, 101, 1544-1552.	3.5	72
54	RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications. <i>Haematologica</i> , 2016, 101, 941-950.	3.5	44

#	ARTICLE	IF	CITATIONS
55	A case of lineage switch from B-cell acute lymphoblastic leukaemia to acute myeloid leukaemia. Role of subclonal/clonal gene mutations. <i>British Journal of Haematology</i> , 2016, 174, 648-651.	2.5	7
56	Deletions of the long arm of chromosome 5 define subgroups of T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2016, 101, 951-958.	3.5	18
57	The genetics of nodal marginal zone lymphoma. <i>Blood</i> , 2016, 128, 1362-1373.	1.4	147
58	CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities. <i>Leukemia Research</i> , 2016, 41, 36-42.	0.8	41
59	Advances in the Genetics and Therapy of Acute Lymphoblastic Leukemia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, e314-e322.	3.8	23
60	How has the management of Ph acute lymphoblastic leukemia (ALL) changed over the years. <i>Rinsho Ketsueki/the Japanese Journal of Clinical Hematology</i> , 2016, 57, 2038-2048.	0.5	1
61	Management of adult Ph-positive acute lymphoblastic leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 406-413.	2.5	33
62	CD45 antigen negativity in T-lineage ALL correlates with <i>PTPRC</i> mutation and sensitivity to a selective JAK inhibitor. <i>British Journal of Haematology</i> , 2015, 171, 884-887.	2.5	4
63	Increased chronic lymphocytic leukemia proliferation upon IgM stimulation is sustained by the upregulation of miR-132 and miR-12. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 222-234.	2.8	26
64	A case of late isolated ovarian relapse of acute lymphoblastic leukemia after an allogeneic stem cell transplant. <i>Leukemia and Lymphoma</i> , 2015, 56, 1517-1520.	1.3	7
65	Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Ph+ Acute Lymphoblastic Leukemia (ALL) Patients. Updated Results and Refined Genetic-Based Prognostic Stratification. <i>Blood</i> , 2015, 126, 81-81.	1.4	44
66	DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014073.	1.3	132
67	DDX3X-MLLT10 fusion in adults with NOTCH1 positive T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2014, 99, 64-66.	3.5	27
68	Genomic Characterization of Acute Leukemias. <i>Medical Principles and Practice</i> , 2014, 23, 487-506.	2.4	23
69	Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B-cell receptor structure, function, and patients' prognosis. <i>American Journal of Hematology</i> , 2014, 89, 74-82.	4.1	20
70	Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. <i>American Journal of Hematology</i> , 2014, 89, 480-486.	4.1	104
71	Whole-genome amplification for the detection of molecular targets and minimal residual disease monitoring in acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2014, 165, 341-348.	2.5	3
72	The epigenetic factor BORIS/CTCF regulates the NOTCH3 gene expression in cancer cells. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2014, 1839, 813-825.	1.9	32

#	ARTICLE	IF	CITATIONS
73	Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. <i>Blood</i> , 2014, 123, 2378-2388.	1.4	78
74	Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. <i>Leukemia Research</i> , 2014, 38, 198-203.	0.8	4
75	<i>NOTCH1</i> , <i>SF3B1</i> , <i>BIRC3</i> and <i>TP53</i> mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment. <i>Leukemia and Lymphoma</i> , 2014, 55, 2785-2792.	1.3	47
76	Genetic profile of T-cell acute lymphoblastic leukemias with <i>MYC</i> translocations. <i>Blood</i> , 2014, 124, 3577-3582.	1.4	49
77	First Results of the Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients. <i>Blood</i> , 2014, 124, 797-797.	1.4	11
78	<i>BIRC3</i> disruption and Copy Number Aberrations in Chronic Lymphocytic Leukemia (CLL) Patients with 11q Deletion. <i>Blood</i> , 2014, 124, 3295-3295.	1.4	3
79	Novel Molecular Acquisitions in Leukemias. , 2013, , 453-493.		0
80	IgD cross-linking induces gene expression profiling changes and enhances apoptosis in chronic lymphocytic leukemia cells. <i>Leukemia Research</i> , 2013, 37, 455-462.	0.8	7
81	Comprehensive Analysis of Transcriptome Variation Uncovers Known and Novel Driver Events in T-Cell Acute Lymphoblastic Leukemia. <i>PLoS Genetics</i> , 2013, 9, e1003997.	3.5	110
82	<i>TP53</i> mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy. <i>Haematologica</i> , 2013, 98, e59-e61.	3.5	56
83	Identification of molecular and functional patterns of p53 alterations in chronic lymphocytic leukemia patients in different phases of the disease. <i>Haematologica</i> , 2013, 98, 371-375.	3.5	15
84	Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. <i>Haematologica</i> , 2013, 98, 1702-1710.	3.5	121
85	<i>ATM</i> gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression. <i>Haematologica</i> , 2012, 97, 47-55.	3.5	92
86	<i>NOTCH1</i> mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL. <i>Haematologica</i> , 2012, 97, 437-441.	3.5	178
87	Dysfunctional $\hat{V}^3\hat{V}^2$ T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. <i>Blood</i> , 2012, 120, 3271-3279.	1.4	51
88	Disruption of <i>BIRC3</i> associates with fludarabine chemorefractoriness in <i>TP53</i> wild-type chronic lymphocytic leukemia. <i>Blood</i> , 2012, 119, 2854-2862.	1.4	257
89	Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for $\hat{\epsilon}$ - and $\hat{\epsilon}$ -combination strategies. <i>Journal of Molecular Medicine</i> , 2012, 90, 1133-1144.	3.9	35
90	<i>IKAROS</i> Deletions Dictate a Unique Gene Expression Signature in Patients with Adult B-Cell Acute Lymphoblastic Leukemia. <i>PLoS ONE</i> , 2012, 7, e40934.	2.5	73

#	ARTICLE	IF	CITATIONS
91	Behind the scenes of non-nodal MCL: downmodulation of genes involved in actin cytoskeleton organization, cell projection, cell adhesion, tumour invasion, <i>TP53</i> pathway and mutated status of immunoglobulin heavy chain genes. <i>British Journal of Haematology</i> , 2012, 156, 601-611.	2.5	21
92	A subset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosis. <i>Experimental Hematology</i> , 2012, 40, 197-206.e1.	0.4	15
93	Functional analysis and gene expression profile of umbilical cord blood regulatory T cells. <i>Annals of Hematology</i> , 2012, 91, 155-161.	1.8	19
94	The Interlaboratory Robustness of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses of Hematological Malignancies Performed by an International Network Involving 26 Laboratories. <i>Blood</i> , 2012, 120, 1399-1399.	1.4	6
95	NOTCH1, SF3B1 and BIRC3 Mutations in Chronic Lymphocytic Leukemia (CLL) Patients Requiring First-LINE Treatment: Correlation with Biological Parameters and Response to Treatment. <i>Blood</i> , 2012, 120, 1784-1784.	1.4	2
96	Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. <i>Blood</i> , 2011, 118, 6904-6908.	1.4	342
97	DNA methyltransferase 3a hot-spot locus is not mutated in pediatric patients affected by acute myeloid or T-cell acute lymphoblastic leukemia: an Italian study. <i>Haematologica</i> , 2011, 96, 1886-1887.	3.5	11
98	<i>AICDA</i> expression in <i>BCR/ABL1</i> positive acute lymphoblastic leukaemia is associated with a peculiar gene expression profile. <i>British Journal of Haematology</i> , 2011, 152, 727-732.	2.5	4
99	Evaluation of <i>TP53</i> mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: Correlation with clinical outcome and gene expression profiling. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 263-274.	2.8	25
100	Critical Role of c-Myc in Acute Myeloid Leukemia Involving Direct Regulation of miR-26a and Histone Methyltransferase EZH2. <i>Genes and Cancer</i> , 2011, 2, 585-592.	1.9	87
101	Myeloid/T-cell acute lymphoblastic leukemia in children and adults. <i>Mental Illness</i> , 2011, 3, 3.	0.8	3
102	Gene expression profiling identifies a subset of adult T-cell acute lymphoblastic leukemia with myeloid-like gene features and over-expression of miR-223. <i>Haematologica</i> , 2010, 95, 1114-1121.	3.5	45
103	Combined interphase fluorescence in situ hybridization elucidates the genetic heterogeneity of T-cell acute lymphoblastic leukemia in adults. <i>Haematologica</i> , 2010, 95, 79-86.	3.5	44
104	ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon. <i>Blood</i> , 2010, 115, 3287-3295.	1.4	24
105	SQSTM1-NUP214: a new gene fusion in adult T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2010, 95, 2161-2163.	3.5	28
106	Protein kinase gene expression profiling and in vitro functional experiments identify novel potential therapeutic targets in adult acute lymphoblastic leukemia. <i>Cancer</i> , 2010, 116, 3426-3437.	4.1	14
107	Gene expression profile of protein kinases reveals a distinctive signature in chronic lymphocytic leukemia and in vitro experiments support a role of second generation protein kinase inhibitors. <i>Leukemia Research</i> , 2010, 34, 733-741.	0.8	12
108	Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Subclassification of Leukemia: Report From the International Microarray Innovations in Leukemia Study Group. <i>Journal of Clinical Oncology</i> , 2010, 28, 2529-2537.	1.6	567

#	ARTICLE	IF	CITATIONS
109	Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 252-257.	7.1	314
110	Adult acute lymphoblastic leukemia. Revista Brasileira De Hematologia E Hemoterapia, 2009, 31, .	0.7	1
111	Characterization of Bâ€and Tâ€lineage acute lymphoblastic leukemia by integrated analysis of MicroRNA and mRNA expression profiles. Genes Chromosomes and Cancer, 2009, 48, 1069-1082.	2.8	87
112	Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1â€positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood, 2009, 114, 2159-2167.	1.4	201
113	<i>IKZF1</i> (Ikaros) Deletions in <i>BCR-ABL1</i>â€Positive Acute Lymphoblastic Leukemia Are Associated With Short Disease-Free Survival and High Rate of Cumulative Incidence of Relapse: A GIMEMA AL WP Report. Journal of Clinical Oncology, 2009, 27, 5202-5207.	1.6	276
114	T-cell acute lymphoblastic leukemia. Haematologica, 2009, 94, 160-162.	3.5	76
115	Growth-Inhibitory and Antiangiogenic Activity of the MEK Inhibitor PD0325901 in Malignant Melanoma with or without BRAF Mutations. Neoplasia, 2009, 11, 720-W6.	5.3	87
116	Spontaneous regression of chronic lymphocytic leukemia: clinical and biologic features of 9 cases. Blood, 2009, 114, 638-646.	1.4	65
117	CRLF2/JAK Signaling in Adult and Pediatric Acute Lymphoblastic Leukemia Is Highly Similar to BCR/ABL.. Blood, 2009, 114, 3461-3461.	1.4	0
118	IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients.. Blood, 2009, 114, 912-912.	1.4	0
119	CRLF2/JAK Signaling Confers Susceptibility to JAK Inhibitors and Small Molecule Inhibitors of Protein Kinase C.. Blood, 2009, 114, 3767-3767.	1.4	0
120	PAX5 Wild-Type without IKZF1 (Ikaros) Deletion Is Associated with Prolonged Disease-Free Survival and Low Rate of Cumulative Incidence of Relapse in Adult BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL): On Behalf of GIMEMA AL Working Party.. Blood, 2009, 114, 12-12.	1.4	2
121	Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. Blood, 2008, 112, 3847-3855.	1.4	99
122	An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase. British Journal of Haematology, 2008, 142, 802-807.	2.5	173
123	Somatically acquired <i>JAK1</i> mutations in adult acute lymphoblastic leukemia. Journal of Experimental Medicine, 2008, 205, 751-758.	8.5	318
124	Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method. Haematologica, 2008, 93, 1814-1821.	3.5	39
125	BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgVH unmutated chronic lymphocytic leukemia (CLL) cells. Blood, 2008, 112, 782-792.	1.4	121
126	ATM Gene Alterations in CLL Patients Induce Gene Profile Clusters and Predict Disease Progression.. Blood, 2008, 112, 2084-2084.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Identification and Molecular Characterization of Two Recurrent Genomic Deletions (Type A and Type) Tj ETQq1 1 0.784314 rgBT /Ove Behalf of the GIMEMA ALL Working Party. Blood, 2008, 112, 428-428.	1.4	0
128	Different Isoforms of the B-Cell Mutator Activation-Induced Cytidine Deaminase (AID) Are Aberrantly Over-Expressed in BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL) Patients and Promote Genetic Instability.. Blood, 2008, 112, 1497-1497.	1.4	0
129	A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing. Cell, 2007, 129, 1401-1414.	28.9	3,390
130	Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood, 2007, 109, 4944-4951.	1.4	471
131	The Role of MicroRNAs in Chronic Lymphocytic Leukemia. Clinical Leukemia, 2007, 1, 287-291.	0.2	0
132	Characterization of ABL1 expression in adult T-cell acute lymphoblastic leukemia by oligonucleotide array analysis. Haematologica, 2007, 92, 619-626.	3.5	12
133	Comparative Gene Profiling of Acute Myeloid Leukemia (AML) and Malignant Melanoma (MEL) Cell Lines Exposed to the MEK Inhibitor PD0325901 Reveals Common Effectors of the MEK/ERK Kinase Module.. Blood, 2007, 110, 3470-3470.	1.4	1
134	IgVH Germline and Mutated Chronic Lymphocytic Leukemia (CLL) Cases Exert a Diverse Responsiveness upon BCR Ligation.. Blood, 2007, 110, 1133-1133.	1.4	1
135	ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 rearrangement and the pre-B stage of differentiation and prognostic implications. Blood, 2006, 107, 197-204.	1.4	30
136	The changing scene of adult acute lymphoblastic leukemia. Current Opinion in Oncology, 2006, 18, 652-659.	2.4	37
137	An International Multi-Center Study To Define the Application of Microarrays in the Diagnosis and Subclassification of Leukemia (MILE Study): Interim Analysis Based on 1,889 Patients Achieves 95.4% Prediction Accuracy.. Blood, 2006, 108, 103-103.	1.4	3
138	The MicroRNA (miR) Profile in B-Cell Chronic Lymphocytic Leukemia (CLL) Reveals a Differential Expression of miR-21, miR-155 and miR-150 between Leukemic and Normal B Lymphocytes, and of miR-150, miR-29bc and miR-223 between IgVH Mutated and Unmutated Patients.. Blood, 2006, 108, 298-298.	1.4	1
139	Molecular and Functional Effects of the Novel MEK Inhibitor PD0325901 in Preclinical Models of Human Leukemias.. Blood, 2006, 108, 254-254.	1.4	0
140	Gene Expression Profile of Protein Kinases Reveals a Distinctive Signature of Chronic Lymphocytic Leukemia (CLL) and Points to a Role of Second Generation Protein Kinase Inhibitors.. Blood, 2006, 108, 2794-2794.	1.4	0
141	Protein Kinase Gene Expression Profile in Adult Acute Lymphocytic Leukemia (ALL): Identification of Novel Therapeutic Targets.. Blood, 2006, 108, 1824-1824.	1.4	0
142	Angiogenic Activity in IgVH Mutated and Unmutated Chronic Lymphocytic Leukemia (CLL): Indications for the Therapeutic Use of VEGF-Signaling Inhibitors.. Blood, 2006, 108, 2819-2819.	1.4	0
143	A broad and integrated diagnostic work-up for a modern management of Acute Lymphoblastic Leukemia (ALL). Hematology, 2005, 10, 55-62.	1.5	1
144	Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. Blood, 2005, 105, 3945-3950.	1.4	94

#	ARTICLE	IF	CITATIONS
145	FLT3 inhibition in t(4;11)+ adult acute lymphoid leukaemia. British Journal of Haematology, 2005, 130, 43-50.	2.5	16
146	Bayesian Error-in-Variable Survival Model for the Analysis of GeneChip Arrays. Biometrics, 2005, 61, 488-497.	1.4	17
147	Gene Expression Profiles of B-lineage Adult Acute Lymphocytic Leukemia Reveal Genetic Patterns that Identify Lineage Derivation and Distinct Mechanisms of Transformation. Clinical Cancer Research, 2005, 11, 7209-7219.	7.0	128
148	Genomic analysis in lymphoid leukemias. Reviews in Clinical and Experimental Hematology, 2005, 9, E3.	0.1	2
149	Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. Blood, 2004, 103, 2771-2778.	1.4	296
150	Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood, 2004, 103, 656-663.	1.4	73
151	Identification of a LOH Region on Chromosome 9p Associated with a Specific Gene Expression Signature in Adult B-Lineage ALL through Integration of High Density Microarray Expression and SNP Analyses.. Blood, 2004, 104, 1119-1119.	1.4	0
152	ZAP-70 Expression in Acute Lymphoblastic Leukemia: Association with the E2A/PBX1 Rearrangement and with the Pre-B Stage of Differentiation.. Blood, 2004, 104, 4305-4305.	1.4	0
153	Human acute stem cell leukemia with multilineage differentiation potential via cascade activation of growth factor receptors. Blood, 2002, 99, 4634-4637.	1.4	14